• vcard
D 314.622.6685
F 314.480.7045
  • Education
    • J.D., summa cum laude, Southern Illinois University, 2006
    • B.S./B.A., magna cum laude, Washington University in St. Louis, 2002
Andrew Speciale is guided by the principle that the foundation of any sound legal advice is a firm understanding of the client’s underlying business. His attention to detail regarding his client’s underlying business allows him to dispense strategic advice on a wide array of business matters.

Andrew works with emerging companies in all phases of their lifecycle, with an emphasis of governance, venture capital financings (debt and equity), strategic relationships, and exit transactions.  

Andrew frequently works with clients in the following areas: life sciences, ag-tech, financial technology and information technology. His experience in the life science industry includes representation of generic pharmaceutical, medical device, medical diagnostic, research service, biochemical product, and agriculture clients.    

In addition to his work with emerging companies, Andrew also brings his attention to detail to his representation of venture capital funds as well as corporate and other investors with respect to fund investment, structure and management in the areas of life sciences, information technology, financial technology, cyber security, agriculture and energy.

As part of his support of clients, Andrew actively works in support of the St. Louis regional effort to support and encourage the establishment, funding, and development of companies operating in these industries.

Andrew has represented clients the following matters:

  • Investments in excess of $100 million by venture funds specializing in early-stage life science, information technology, and financing technology companies  
  • Multiple emerging corporate clients (in the life sciences, ag-tech, information technology, and financial technology spaces) in raising in excess of $200 million of capital from venture capital funds, angel investors, angel investor networks, non-profit corporations, state agencies, and regional and national accelerators.
  • An enzymes development company in a multiple million dollar collaboration with a major agro-chemical company.
  • Represented a software company in an exit transaction valued in excess of $30 million. 
  • Multiple emerging life sciences companies with respect to university license agreements, research agreements, master services agreements, sponsored research agreements, material transfer agreements, confidentiality agreements, consulting agreements and other licenses and agreements. 
  • An emerging medical diagnostics company in a capital raise in excess of $35 million.
  • Represented buyers of early-stage technologies in distressed asset transactions.
  • A consumer goods packaging company with the review, analysis, and negotiation of supply agreements and related commercial contracts.
text icon Publications & Presentations
Lying to Regulators . . . What's the Risk?
Co-authored by Larry Harris and Andrew Speciale
August 2013
Related News

Past Events